Kornimate/medical-research-clean huggingface dataset:
thumb-ecg ambulant screening for atrial fibrillation in patients treated for hyperthyroidism (tambourine)

Conditions: Hyperthyroidism; Atrial Fibrillation

Summary: background: atrial fibrillation is a common heart rhythm disturbance affecting some 1-2% of the western population. it may cause symptoms such as irregular heartbeats, shortness of breath, and fatigue. it may also be asymptomatic (ie "silent atrial fibrillation). in some cases, atrial fibrillation is permanent whereas in others it is sporadic. regardless of symptoms, there is an increased risk of stroke in some patients with this condition. novel technologies are being developed to increase detection of silent atrial fibrillation, in order to find patients who might benefit from treatment with oral anticoagulants (blood-thinning medications) in order to reduce the risk of stroke. one of these technologies is thumb-ecg, a simple way for a patient to have his or her heart rhythm reliably analyzed at home. hyperthyroidism (sometimes referred to as "toxic goiter") is defined as an excessive production of thyroid hormone. it is known that hyperthyroidism may cause atrial fibrillation in about 8% of cases. objective: to provide thumb-ecg-monitors to hyperthyroid patients before and after treating their hormonal disturbance, in order to find episodes of silent atrial fibrillation. design: prospective observational study. hypotheses: * primary hypothesis: silent atrial fibrillation is at least as common as overt atrial fibrillation in hyperthyroid patients. * secondary hypothesis nr 1: atrial fibrillation continues to be more prevalent compared to the normal population even after hyperthyroidism is treated. * secondary hypothesis nr 2: the majority of patients with hyperthyroidism and atrial fibrillation are at increased risk of stroke and should be considered for treatment with oral anticoagulants.


Eligibility criteria:
inclusion criteria: * patient is deemed suitable for treatment with radioiodine or antithyroid drugs * patient has a thyreotropin (tsh) value below 0,1 miu/l, measured less than 2 weeks before inclusion * patient has a chads-vasc-score of 1 point or higher (excluding if 1 point is for female sex only) * patient gives written consent to participate in study exclusion criteria: * patient has a previously known diagnosis of atrial fibrillation
study of pemetrexed + carboplatin + bevacizumab + enzastaurin versus pemetrexed + carboplatin + bevacizumab + placebo in participants with non-small cell lung cancer who have not been previously treated with chemotherapy

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this study is to determine if pemetrexed plus carboplatin plus bevacizumab plus enzastaurin, followed by maintenance bevacizumab plus enzastaurin can extend survival time without disease progression in the first-line treatment of participants with advanced stage non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * participants or their legal representative must have signed an informed consent document for clinical research * have laboratory confirmed diagnosis of advanced, nonsquamous cell non-small cell lung cancer (nsclc) (stage iiib or iv disease) which is not curable * have not received any prior systemic chemotherapy, immunotherapy, targeted therapy, or biological therapy for advanced nsclc, prior radiation therapy is allowed to less than 25% of the bone marrow * have measurable disease * have adequate organ function and estimated life expectancy of 12 weeks exclusion criteria: * have known central nervous system (cns) disease; major surgery within 28 days; minor surgery within 7 days; serious concomitant systemic disorder; serious cardiac condition; have a serious, nonhealing wound, ulcer, or bone fracture * have received treatment within the last 30 days with any drug that has not received regulatory approval for any indication at the time of study entry * have previously received treatment with enzastaurin, pemetrexed, or bevacizumab * are pregnant or breast-feeding * are unable to swallow tablets
endoscopic ultrasound-guided celiac plexus neurolysis in the management of pain in abdominal non-pancreatic malignancies

Conditions: Pain; Cancer

Summary: celiac plexus neurolysis (cpn) has been performed for nearly 100 years to alleviate the abdominal pain associated with pancreatic malignancy and other conditions, and is usually undertaken at a late stage in the disease process, when analgesic options have been largely exhausted or have led to significant and often unacceptable side effects. until recently, cpn was most commonly performed under radiographic guidance; however, in the last 10 years, cpn has been routinely performed under endoscopic ultrasound (eus) guidance. several case series have demonstrated the efficacy and safety of this technique when used to treat the pain associated with pancreatic malignancy and/or chronic pancreatitis. however, the efficacy of eus-guided cpn in the treatment of pain related to non-pancreatic malignancies has yet to be described. the goal of this study is to assess the efficacy of eus-guided cpn in the management of pain in patients with abdominal non-pancreatic malignancies. our hypothesis is that eus-guided cpn will provide adequate pain relief in these patients.


Eligibility criteria:
inclusion criteria: * diagnosis of an unresectable, non-pancreatic malignancy, including gastric, small intestinal, or proximal colonic malignancies, as well as malignancies of the liver and bile ducts (based on above celiac plexus innervations) * pain directly related to the primary malignant process, as determined by the referring oncologist * pain determined to be refractory to standard medical therapy, or when the medical therapy is ineffective due to certain limitations (such as severe constipation), as determined by the referring oncologist * willingness to undergo eus-guided cpn * age \> 18 years * ecog performance status of grades 0-3 \[7\] * the patient will need to sign informed consent prior to inclusion in this study exclusion criteria: * unable or unwilling to undergo an eus-guided cpn * contraindication to anesthesia, as determine during the preoperative clearance process * refractory coagulopathy (inr \> 1.5) or thrombocytopenia (platelet count \< 50,000), or aspirin and/or clopidogrel use within 7 days of procedure * current pregnancy * prior celiac plexus block/neurolysis * allergy to local anesthetics * ecog performance status of grade 4 or higher
integrative omics analysis for colorectal cancer and metastasis

Conditions: Colorectal Cancer

Summary: the pathogenesis of colorectal cancer (crc) metastasis remains unclear.we collect clinical data from our center and use integrative omics to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.

colorectal cancer (crc), one of the most common malignant cancer around the world, crc patients with distant metastasis. however, the pathogenesis of metastasis remains unclear. integrative omics have begun to enable personalized medicine at an extraordinarily detailed molecular level. all patients with colorectal cancer and metastasis in our center who meet the inclusion criteria and exclusion criteria will be enrolled. the specimen collected by surgery and clinical data will be collected . we use integrative omics such as rna-sequencing,atac-seq(assay for transposase-accessible chromatin using sequencing), cut\&tag（ cleavage under targets and tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis. this study will contribute to understanding the molecular mechanism of crc metastasis in depth and contribute to the discovery of new appropriate molecular diagnostic and therapeutic targets, and more accurately prognose long term outcome in patients with crc.

Eligibility criteria:
inclusion criteria: * colorectal adenocarcinoma by biopsy。 * at least 1 metastasis lesion comfirmed by at least 1 kind of imaging examination (ct, mri and pet-ct ) exclusion criteria: * recent diagnosis with other malignancies * can not tolerate the surgery * history of serious mental illness * pregnancy or lactating women * the researchers believe the patients should not enrolled in

Keywords: integrative omics colorectal cancer distant metastasis prognostic analysis
face masks to reduce the adverse effects of diesel exhaust inhalation

Conditions: Healthy

Summary: air pollution exposure is a major environmental and public health concern. the findings from controlled exposure studies have given biological plausibility to the epidemiological associations, and have defined important pathways that may be amenable to intervention. ultimately, there is a need to address how one may protect the public from these detrimental effects. two studies have been performed assessing the cardiovascular effects of wearing a face mask in a highly polluted urban area in china in healthy volunteers and patients with coronary heart disease. these demonstrated lower blood pressure and increased heart rate variability when wearing a face mask as compared to not. the investigators aim to test if wearing a highly efficient face mask during exposure to dilute diesel exhaust abrogates the well-known adverse cardiovascular effects.


Eligibility criteria:
inclusion criteria: * healthy males * non-smoking * all subjects undergo a general health examination and are required to have normal clinical examination, ecg, blood tests and lung function exclusion criteria: * metabolic or cardiovascular disease * asthma or other respiratory disease * respiratory infection within 2 weeks of the study * antioxidant- and/or vitamin supplementation within 1 week prior to, as well as during the course of the study. (incl vitamin c, acetylcysteine) * smokers or regular snus usage

Keywords: diesel exhaust air pollution intervention plethysmography
detection of anti-covid-19 antibody levels in an hospital population

Conditions: COVID-19

Summary: covid-19 (sars-cov-2) infection in health professionals represent a significant criticality both for the risk of spreading the disease and for the organizational aspects that follow. the objective of the study is to evaluate the spread of covid-19 virus within the hospital population of humanitas through the monitoring of the levels of igg antibodies. moreover, viral load will be measured by rt-pcr in the subgroup positive to igg antibodies.

the coronavirus identified in wuhan, china, for the first time in late 2019 is a new viral strain that has never previously been identified in humans. it has been called sars-cov-2 and the respiratory disease that causes covid-19. sars-cov-2 infection in health professionals has represented and continues to represent a significant criticality both for the risk of spreading the disease and for the organizational aspects that follow. currently the gold standard for the non-invasive diagnosis of covid-19 is the detection of the viral genome by rt-pcr. however, despite the high specificity, this technique has a low sensitivity and can produce false negative samples. furthermore, detection of the viral genome is indicative of active infection and fails to identify subjects previously exposed to the virus who have passed the infection asymptomatically. serological tests can detect the presence of anti-sars-cov-2 antibodies in blood or serum samples and, depending on the type of antibody detected, identify the subjects in the active phase of the infection and after the resolution of the infection, the whose diagnosis was not made by performing a swab. we will evaluate the actual spread of the sars-cov-2 virus within the hospital personnel of humanitas through the monitoring of the levels of igg antibodies. moreover, viral load will be measured by rt-pcr of nasopharyngeal swabs in the subgroup positive to igg antibodies. secondary endpoints are: visualize the trend of the antibody value at 3, 6 and 12 months; correlation between the antibody titer in test positive subjects and the viral load of the nasopharyngeal swab; identification of predictive variables of susceptibility to viral sars-cov2 infection.

Eligibility criteria:
inclusion criteria: * age\> 18 years old * work for the humanitas group (rozzano / san pio x, humanitas gavazzeni, humanitas mater domini, humanitas university, humanitas medical care) * work activity in the humanitas group for at least 3 months among which, for example: healthcare staff (doctors, nurses, oss) technical staff (biologists, radiology technicians, laboratory technicians, etc.) parc staff and staff staff research internship students of hunimed contract staff (e.g. transport and sanitation services) * signature of informed consent * compilation of the anamnestic questionnaire exclusion criteria: * subjects absent for any reason during the study period

Keywords: covid-19 antibody titer serological tests hospital personnel
alloshrink - standard chemotherapy regimen and immunotherapy with allogeneic nkg2d-based cyad-101 chimeric antigen receptor t-cells

Conditions: Unresectable Metastatic Colorectal Cancer

Summary: the purpose of the alloshrink study is to assess the safety, cell kinetics and clinical activity of cyad-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

this study aims to determine and confirm the recommended dose of the allogeneic cyad-101 cells after standard folfox or folfiri chemotherapy in patients with unresectable metastatic colorectal cancer

Eligibility criteria:
inclusion criteria: 1. histologically proven metastatic adenocarcinoma of the colon or rectum. 1. confirmed metastatic unresectable adenocarcinoma of the colon or the rectum. 2. recurrent/progressing disease after at least one line of systemic therapy for metastatic disease. 3. unequivocal and measurable disease by response evaluation criteria in solid tumors (recist version 1.1). 4. folfox segment: neurotoxicity less than or equal to common terminology criteria for adverse events (ctcae) grade 1 from previous chemotherapy. 5. folfiri segment: documented progressive disease (pd) under folfiri treatment, with or without targeted therapy, given within 3 months prior to study registration. anti-cancer therapy post folfiri-documented pd prior to study registration is authorized if discontinued at least 7 days before the planned study registration. radiotherapy is not authorized. 2. the patient must have an eastern cooperative oncology group (ecog) performance status 0 or 1. 3. the patient must have adequate bone marrow reserve, hepatic, renal, pulmonary and cardiac functions. exclusion criteria: 1. the patient has a confirmed or history of tumor involvement in the central nervous system (cns). 2. any non-cancer-directed investigational agent within 3 weeks before the planned day for the first cyad-101 administration. 3. filgrastim (granulocyte-colony-stimulating factor \[g-csf\]) or similar growth factors within 7 days before the planned day for the first cyad-101 administration. 4. prior allogeneic stem cell transplantation, chimeric antigen receptor therapy or other genetically modified t-cell therapy.
rct evaluating standardized counseling on early discontinuation for irregular bleeding in nexplanon users

Conditions: Birth Control; Contraception; Contraceptive Usage; Family Planning

Summary: clinician counseling for implant users should involve an explanation of the likelihood of irregular bleeding and the possibility of continued or frequent bleeding throughout three years of use. if that counseling does not provide specifics of the actual distribution of bleeding patterns described in published literature, there remains the real possibility of biased or directed counseling, leading to an inaccurate and exaggerated expectation of potential bleeding changes. this study aims to evaluate if a standardized script accompanied by a visual aid regarding expected bleeding profiles, with intention to remove any possibility of negative or positive framing, could change users' expectations and satisfaction with their method, leading to lower discontinuation rates.


Eligibility criteria:
inclusion criteria: * presenting at the health center to receive an etonogestrel-releasing subdermal implant (nexplanon) for primarily contraceptive benefits * ability to consent in english exclusion criteria: * have used an etonogestrel-releasing subdermal implant (nexplanon) within the 12 weeks prior to enrollment

Keywords: contraceptive implant birth control nexplanon
computational assessment of bioprosthetic aortic valve function

Conditions: CFD; Valve Heart Disease

Summary: bioprosthetic valves are usually made of biological tissue that are mounted to a frame and are designed to function similarly to a healthy natural valve. edwards magna ease and intuity elite bioprosthetic valves have similar leaflets and mounting designs. however, the valves are implanted in the patient in different ways (one is stitched to the wall of the left ventricular outflow tract, and the other is held in place by the radial force of the valve skirt). the study aims to understand in more detail how the different valves interact with the left ventricular outflow tract and aortic root.

the implantation of a bioprosthetic valve is the established surgical technique when replacing the aortic valve to treat various aortic valve diseases. many different bioprosthetic valves are available. the design and implantation technique in each system would result in different interaction with the left ventricular outflow tract (lvot) and the aortic root, leading to different flow profiles that may induce platelet aggregation and affect the long-term performance of the bioprosthesis and its durability. additionally, complications such as valve thrombosis may occur. however, it is not currently clear which bioprostheses/patients are more prone to thrombosis or degradation of the valve. this study aims to develop fluid-structure interaction (fsi) models, which can model blood flow and wall/valve mechanics, using realistic patient-specific geometries and flow conditions which correlate with the true performance of the valve in the imaged patients, and to assess and compare such performances to understand the benefits and challenges with various bioprosthetic valves. fsi models combine computational fluid mechanics (cfd) with structural wall mechanics modelling. this is an alternative approach that allows detailed assessment of flow patterns and estimation of wall shear stress and pressure within blood vessels, and therefore has been applied increasingly to gain better insights into the hemodynamics in cardiovascular diseases

Eligibility criteria:
inclusion criteria: * male and female patients aged 18 years or over. * patients diagnosed with aortic valve disease, and scheduled to undergo edwards magna ease or intuity elite and free of exclusion criteria below. * the patient is willing and able to understand the patient information sheet and provide written informed consent. * the patient must agree to comply with the study imaging protocol as required at prespecified times. exclusion criteria: * inability to provide valid informed consent. * male and female patients aged \< 18 years of age. * contraindications for ct angiography: renal failure (cr\>250 μmol/l or egfr\<30 ml/min) due to the additional risk of contrast medium nephrotoxicity or allergy to iodine. * women of childbearing age who have not had a hysterectomy and/or who may be breastfeeding. * history of cardiac pacing device insertion, or any other mri incompatible device implants.

Keywords: bioprosthesis
a safety and efficacy study of infliximab (remicade) in patients with plaque type psoriasis

Conditions: Psoriasis

Summary: the purpose of the study is to evaluate the effectiveness and safety of infliximab (remicade) in patients with plaque-type psoriasis.

the purpose of this study is to investigate the safety and possible usefulness of infliximab therapy for patients with severe plaque psoriasis. in a previous small study of infliximab in 33 patients with psoriasis, about 80% of patients treated with infliximab showed improvement in their psoriasis symptoms after the first 3 infusions, while 20% of patients who received placebo showed improvement. the patients will receive infusions of infliximab either 3 or 5 mg/kg or placebo at weeks 0,2,6. patients who have significant psoriasis at week 26 will receive an additional infusion.

Eligibility criteria:
inclusion criteria: * must be 18 years of age or older at time of enrollment * may be male or female * have had a diagnosis of plaque-type psoriasis at least 6 months prior to screening * have plaque-type psoriasis covering at least 10% of total bsa at baseline * have previously received puva and/or other systemic treatment for psoriasis exclusion criteria: * have non-plaque forms of psoriasis * have a history of drug-induced psoriasis * are pregnant, nursing, or planning pregnancy within 12 months of enrollment * have had any previous treatment with infliximab or any therapeutic agent

Keywords: plaque-type psoriasis infliximab remicade biologics
efficacy of multigrain supplementation in type ii diabetes mellitus

Conditions: Type2 Diabetes

Summary: the objective of this study is to evaluate the efficacy of instant multigrain supplementation on the glycemic status, cardiometabolic implications, oxidative stress and nutritional status in type ii dm patients.

type ii dm is a highly prevalent and heterogeneous condition. new treatment modalities to complement existing interventions are therefore of great interest, including dietary interventions for primary prevention or as a possible therapeutic option that may confer beneﬁts beyond currently recommended conventional therapies. hence, the present work aims to evaluate the efficacy of instant multigrain supplementation on the glycemic status, cardiometabolic implications, oxidative stress and nutritional status in type ii dm patients, as compare to standardized medication regimen.

Eligibility criteria:
inclusion criteria: inclusion criteria for the clinical trial are: * clinical diagnosis with type ii dm for at least 6 months' duration without clinically manifest complications (retinopathy, diabetic nephropathy, vascular diseases, foot ulcer - as diagnosed by the physician/recorded in database) * male or female * pharmacological treatment with metformin or insulin, or a combination of metformin and glibenclamide. * chronological age: 18 years and above * metabolically stable (current laboratory results for a1c 6.0-8.5%; or fasting plasma glucose 6.4-8.5 mmol/l) * not taking antioxidant/anti-inflammatory supplements (example of antioxidant: vitamin c, vitamin e, grape seed extract, garlic capsule, ginkgo biloba) (example of anti-inflammatory supplement: fish oil, curcumin extract, ginger extract, spirulina) exclusion criteria: * having liver (chronic liver failure, cirrhosis, all types of hepatitis), kidney (chronic kidney disease, haemodialysis) or haematological (anaemia, thalassemia, haemophilia) disorders * active gastric/duodenal ulcer * psychiatric disease/mental retardation (bipolar disorder, depression, schizophrenia) * cancer (all types), and endocrine disorders (cushing's disease, gigantism and hyperthyroidism). * alcohol and drug abuse (self-mentioned or as recorded in the medical card) * gestational diabetes mellitus * pregnancy/lactation * hormone replacement therapy (for at least 3 months prior to entering the study) * herbal remedies (any parts from the plants such as flowers, rhizome, seeds, roots, leaves, fruits, stems) * use of steroids, chemotherapy, immunosuppressant or radiotherapy. * vegetarian patient (pure vegan) * gluten intolerance * participations currently under another supplementary program